Regulation of CD45 Alternative Splicing by Heterogeneous Ribonucleoprotein, hnRNPLL

Department of Pathology, Immune Disease Institute, Harvard Medical School, Boston, MA 02115, USA.
Science (Impact Factor: 31.48). 09/2008; 321(5889):686-91. DOI: 10.1126/science.1157610
Source: PubMed

ABSTRACT The transition from naïve to activated T cells is marked by alternative splicing of pre-mRNA encoding the transmembrane phosphatase
CD45. Using a short hairpin RNA interference screen, we identified heterogeneous ribonucleoprotein L-like (hnRNPLL) as a critical
inducible regulator of CD45 alternative splicing. HnRNPLL was up-regulated in stimulated T cells, bound CD45 transcripts,
and was both necessary and sufficient for CD45 alternative splicing. Depletion or overexpression of hnRNPLL in B and T cell
lines and primary T cells resulted in reciprocal alteration of CD45RA and RO expression. Exon array analysis suggested that
hnRNPLL acts as a global regulator of alternative splicing in activated T cells. Induction of hnRNPLL during hematopoietic
cell activation and differentiation may allow cells to rapidly shift their transcriptomes to favor proliferation and inhibit
cell death.

Download full-text


Available from: Luis F. Moita, Jan 05, 2015
  • Source
    • "Thus, a pre-selection of cells based on their low side scatter (SSC, i.e. their content of organelles capable of scattering the laser light) and their CD45 expression is often employed in multicolour assays. The latter surface marker has served as a model for protein isoforms generation by alternative splicing (Oberdoerffer et al, 2008) and is usually, but by no means always, expressed in decreased amounts on leukaemic cells (Borowitz et al, 1993; Lacombe et al, 1997; Miyachi et al, 1999). As will be seen from Fig 1, the CD45low/SSClow can be an important way of focusing on the AML blasts and has been proven to significantly increase the sensitivity of the MFC approach (Kern et al, 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The concept of minimal residual disease in acute myeloid leukaemia has been steadily developed pre-clinically, with quantitative polymerase chain reaction (qPCR) leading the way with highly validated assays for patient-based risk stratification at post-treatment time points, which are being integrated in clinical trials both at evaluation of first complete remission (CR1) and after attaining CR1. Moreover, multicolour flow cytometry (MFC) has been increasingly employed in identifying leukaemia-associated immunophenotypes (LAIPs) with significant progress being made in standardization. In translating these widely varying methodologies to parameters useful for individualized patient decision-making, one of the obstacles has been that the assays entail varying sensitivities dependent on a number of variables. For qPCR, sensitivity depends on target type (i.e. fusion transcript, mutated gene or even overexpressed gene) and - in the case of overexpressed genes - on expression in healthy haematopoiesis. For MFC, sensitivity is likewise largely a function on whether the same phenotype is seen in normal immature cells and, in addition, antigen drift/shift with LAIPs changing at relapse is a well-known problem. In considering which sensitivity to opt for, a further variable is the situation of patient, most importantly the level of cytoreduction intended. Here we will attempt to give an overview of these pertinent questions intended for the practicing haematologist, focusing on where the field is heading at the clinical level.
    British Journal of Haematology 06/2012; 158(5):569-80. DOI:10.1111/j.1365-2141.2012.09203.x · 4.96 Impact Factor
  • Source
    • "Others have used exon arrays to investigate alternative splicing differences between normal and diseased tissues (Gardina et al. 2006; French et al. 2007), in the presence of a stimulus (McKee et al. 2007), or instances of tissue-specific alternative splicing (Clark et al. 2007). To date, relatively few transcription and/or splicing factors' functions have been investigated by exon array analysis (Hung et al. 2008; Oberdoerffer et al. 2008; Xing et al. 2008; Sun and Li 2009; Warzecha et al. 2009). In the work presented here, Tat-SF1 depletion led to many changes in overall transcript levels, with the overwhelming majority of these genes showing decreased expression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tat specific factor 1 (Tat-SF1) interacts with components of both the transcription and splicing machineries and has been classified as a transcription-splicing factor. Although its function as an HIV-1 dependency factor has been investigated, relatively little is known about the cellular functions of Tat-SF1. To identify target genes of Tat-SF1, we utilized a combination of RNAi and exon-specific microarrays. These arrays, which survey genome-wide changes in transcript and individual exon levels, revealed 450 genes with transcript level changes upon Tat-SF1 depletion. Strikingly, 98% of these target genes were down-regulated upon depletion, indicating that Tat-SF1 generally activates gene expression. We also identified 89 genes that showed differential exon level changes after Tat-SF1 depletion. The 89 genes showed evidence of many different types of alternative exon use consistent with the regulation of transcription initiation sites and RNA processing. Minimal overlap between genes with transcript-level and exon-level changes suggests that Tat-SF1 does not functionally couple transcription and splicing. Biological processes significantly enriched with transcript- and exon-level targets include the cell cycle and nucleic acid metabolism; the insulin signaling pathway was enriched with Tat-SF1 transcript-level targets but not exon-level targets. Additionally, a hexamer, ATGCCG, was over-represented in the promoter region of genes showing changes in transcription initiation upon Tat-SF1 depletion. This may represent a novel motif that Tat-SF1 recognizes during transcription. Together, these findings suggest that Tat-SF1 functions independently in transcription and splicing of cellular genes.
    RNA 03/2011; 17(4):665-74. DOI:10.1261/rna.2462011 · 4.62 Impact Factor
  • Source
    • "For example, activation through Ras-and protein kinase C-dependent pathways results in altered phosphorylation status of SR proteins leading to changes in activity or subcellular localization (Blaustein et al., 2005; Lynch and Weiss, 2000; Blaustein et al., 2004). More recently, a master regulator of activation-induced splice changes in T cells, hnRNPLL, was identified and found to be necessary for CD45 alternative exon splicing (Oberdoerffer et al., 2008; Topp et al., 2008; Wu et al., 2008). Thus, environmental signals may affect expression, secondary modifications and trafficking of mammalian CD45 splicing regulator proteins or the activity of modulating kinases. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In mammals, expression of the three alternatively spliced exons of the tyrosine phosphatase CD45 is regulated by the developmental and activation state of the cell. In comparison, the channel catfish, Ictalurus punctatus, CD45 homolog contains 18 functional alternatively spliced exons. Since very little is known about CD45 regulation in ectothermic vertebrates, this study examines the regulation of catfish CD45 mRNA isoform expression in clonal T and B cells in response to stimulation. Results show that mitogenic stimulation using catfish serum or concanavalin A induced expression of mRNAs for small CD45 isoforms, and isoform message expression was growth curve dependent, i.e. cells in logarithmic phase express message for smaller CD45 isoforms, whereas stationary phase cells express message for longer CD45 isoforms. In addition, cells treated with the protein synthesis inhibitor cycloheximide expressed message for longer CD45 isoforms, and treatment with lactacystin, which blocks protein degradation, rescued smaller isoform message expression. Collectively these data suggested that expression of CD45 isoforms, in catfish, at least at the mRNA level, is "constitutively dynamic" and highly dependent on extracellular stimuli.
    Developmental and comparative immunology 10/2010; 34(10):1109-18. DOI:10.1016/j.dci.2010.06.003 · 3.71 Impact Factor
Show more